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Abstract
Aim To compare all-cause mortality, stroke recurrence and functional outcomes in people who have experienced
stroke, with and without diabetes.
Methods We captured data on population-based ischaemic strokes (2006–2012) in Nueces County, Texas. Data were
collected from participant interviews and medical records. Differences in cumulative mortality and stroke recurrence risk
by diabetes status were estimated at 30 days and 1 year using Cox models. Differences in 90-day functional outcomes
(activities of daily living/instrumental activities of daily living score: range 1–4; higher scores worse) by diabetes status
were assessed using Tobit regression. Effect modification by ethnicity was examined.
Results There were 1301 ischaemic strokes, 46% with history of known diabetes. The median (interquartile range) age
was 70 (58–81) years and 61% were Mexican American. People with diabetes were younger and more likely to be
Mexican American compared with those without diabetes. After adjustment, diabetes predicted mortality (30-day
hazard ratio 1.44, 95% CI 0.97–2.12; 1-year hazard ratio 1.47, 95% CI 1.09–1.97) but not stroke recurrence (1-year
hazard ratio 1.27, 95% CI 0.78–2.07). People with diabetes had a worse functional outcome score that was explained by
cardiovascular risk factors and pre-stroke factors. Diabetes was not associated with functional outcome in the fully
adjusted model (final adjusted activities of daily living/instrumental activities of daily living score difference 0.11, 95%
CI –0.07 to 0.30). Effect modification by ethnicity was not significant (P>0.3 for all models).
Conclusions Diabetes was associated with higher mortality and worse functional outcome but not stroke recurrence.
Interventions are needed to decrease the adverse outcomes associated with diabetes, particularly in Mexican-American
people.
Diabet. Med. 35, 1249–1257 (2018)
Introduction
Stroke is a major cause of disability in the USA [1]. A
dramatic increase in the prevalence and cost of stroke is
predicted to occur over the next few decades as the
population ages [2]. Reducing the stroke burden in the
USA will demand not only better control of risk factors and
prevention, but also more effective interventions to improve
outcomes following stroke.
Although diabetes is a well-established risk factor for
incident ischaemic stroke [3], results regarding its role in
stroke outcomes have been inconsistent. Some reasons for
discrepant results between studies include differences in
study populations, length of follow-up, selection of covari-
ates to account for possible confounding, and methods for
ascertaining diabetes and stroke outcome status. Because the
prevalence of diabetes is expected to increase dramatically
over the next few decades, it is important to evaluate
comprehensively the effect of diabetes on multiple stroke
outcomes, preferably in population-based studies, which
have been limited to date [4].
Mortality has been extensively studied as a stroke out-
come, but a number of studies have considered only the
crude association between diabetes and mortality, which
limits the interpretability of the estimates. Among studies
that have adjusted for confounders, some but not all
population-based studies have found diabetes to be a
significant predictor of 30-day [5–7] and 1-year mortality
[6–10]. Understanding predictors of stroke mortality remains
important, but the declining stroke mortality in the USA [1]
suggests a need for a broader focus on improving patient-
centred outcomes among stroke survivors, such as stroke
recurrence and functional outcomes.
Fewer studies have assessed the effect of diabetes on stroke
recurrence. Because the rate of stroke recurrence is low, lack
of power is a significant limitation for estimating the effect ofCorrespondence to: Lynda Lisabeth. E-mail: llisabet@umich.edu.
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diabetes on stroke recurrence in individual studies. A 2015
meta-analysis of 14 studies found a significantly increased
hazard ratio of 1.44 (95% CI 1.28, 1.61) for the effect of
diabetes on stroke recurrence after ischaemic stroke [11];
however, the majority of the studies in this meta-analysis
were older, including studies conducted in the 1980s and
1990s, and many were focused on very select populations.
Further, the meta-analysis included results from only one
population-based study, which considered a combined
ischaemic and haemorrhagic stroke population identified
for the period 1995 to 2008. Thus, contemporary data from
population-based studies on the association of diabetes with
stroke recurrence are lacking.
The effect of diabetes on functional outcome has been
more consistent, with most but not all population- and
registry-based studies finding that diabetes predicts worse
function or disability after ischaemic stroke [5,10,12–15];
however, the majority of these studies were not specifically
designed to investigate differences in outcome by diabetes
status and therefore, confounding of the diabetes association
by other factors was not explicitly considered. Further, in the
few studies that sought to estimate the association between
diabetes and functional outcome, adjustment for confound-
ing factors was accomplished through a backwards selection
procedure or by including all adjustment factors in a
multivariable model simultaneously [5,14]. Use of these
methods precludes an understanding of the reasons for worse
functional outcome among people with diabetes who expe-
rience stroke, information that could aid in the design of
post-stroke recovery strategies for those with diabetes.
Diabetes is a nationwide problem but disproportionately
affects minorities. Mexican-American people have a higher
prevalence of diabetes than non-Hispanic white people and
experience worse post-stroke outcomes [15]. Additionally,
Mexican-American people may have greater genetic suscep-
tibility to insulin resistance and poorer access to care than
non-Hispanic white people, which could lead to more severe
diabetes and worse stroke outcomes [16–18]. If ethnicity
modifies the association between diabetes and stroke out-
comes, it would identify a need for targeted interventions for
Mexican-American people with diabetes who experience
stroke.
Given the inconsistent findings to date and lack of
population-based research in diverse populations and in
Mexican-American people specifically, the primary objective
of the present study was to test whether people with diabetes
who experience ischaemic stroke have poorer stroke out-
comes than those without diabetes in a bi-ethnic population-
based stroke study. We hypothesized that people with
diabetes would have higher mortality, higher stroke recur-
rence, and worse functional outcome than people without
diabetes. Additionally, we hypothesized that diabetes would
have a greater impact on stroke outcomes in Mexican-
American people compared with non-Hispanic white people.
Additional background on the literature linking diabetes to
stroke outcomes is included in the Supporting Information
(File S1).
Participants and methods
Data are from the Brain Attack Surveillance in Corpus
Christi (BASIC) project, a population-based stroke surveil-
lance study in Nueces County, Texas. Nueces County is a
geographically isolated bi-ethnic and non-immigrant com-
munity with a population of roughly 350 000, the majority
of whom are Mexican American. The methods used in the
BASIC project have been described previously [19]. Briefly,
trained abstractors identified stroke cases through active and
passive surveillance methods. All possible strokes were
validated by stroke fellowship-trained physicians blinded to
race/ethnicity. Strokes were identified between April 2006
and June 2012. Only ischaemic stroke cases, defined by a
standard clinical definition, were included. Exclusion criteria
for the BASIC project included age <45 years, traumatic
stroke, and residence outside of Nueces County. All those
with ischaemic stroke were approached for participation in
an in-person baseline interview and had their medical records
reviewed. If an individual was unable to complete the
interview, a proxy interview was conducted. Only those
with a complete baseline interview were included. People
with a race/ethnicity other than Mexican American or non-
Hispanic white were excluded because of small numbers.
Stroke outcomes
Stroke outcomes included all-cause mortality, recurrent
stroke and functional outcome. All-cause mortality was
ascertained through the Texas Department of State Health
Services and linked to participants in the BASIC project using
first and last name, date of birth, sex, race/ethnicity and
permanent address. Recurrent strokes, defined as a newly
validated ischaemic stroke or intracerebral haemorrhage
What’s new?
• Although diabetes is an established risk factor for
incident ischaemic stroke, its role in stroke outcomes
remains uncertain, with inconsistent findings across
studies and limited data from diverse, population-based
studies.
• In our ethnically diverse population-based study, we
found that diabetes was associated with higher stroke
mortality and worse functional outcome but not with
stroke recurrence.
• Results suggest that interventions are needed to
decrease the adverse stroke outcomes associated with
diabetes, particularly in Mexican-American people who
experience a high prevalence of diabetes.
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after the initial ischaemic stroke, were ascertained through
BASIC surveillance methods. If an individual had multiple
recurrent strokes, only the first was considered. Beginning in
November 2008, participants were followed for their
outcomes at 90 days. Self-reported scales measuring activities
of daily living (ADLs) and instrumental activities of daily
living (IADLs) were used to assess functional outcome. ADLs
included walking, bathing, grooming, eating, dressing, mov-
ing, and toileting. IADLS included pulling/pushing, stooping,
lifting, reaching, getting up from stopping, standing up after
sitting, walking up one stair, writing or handling small
objects, walking a quarter mile, walking up 10 steps, using a
telephone, managing money, doing all cooking, doing heavy
housework, and doing all shopping. Participants or proxies
self-reported the level of difficulty they experienced with the
seven ADLs and 15 IADLS. Response options included 1 (no
difficulty), 2 (some difficultly), 3 (a lot of difficulty), and 4
(can only do with help). Responses were used to create an
average score, with higher scores representing worse func-
tional outcome. To further aid in the interpretation of the
functional outcome results, we re-ran models dichotomizing
functional outcome as dependent (average ADL/IADL score
≥3) vs independent (average ADL/IADL score<3).
Diabetes and other variables
History of known diabetes mellitus was ascertained from the
medical record. This method has shown good agreement
(j=0.86) with self-report of diabetes in this community [20].
Baseline interview data included race/ethnicity, marital status
(married or living together, single, widowed, divorced or
separated), education (lower than high school level vs high
school or higher), pre-stroke function (modified Rankin
scale, categorized as 0–1, 2–3, 4–6; higher scores represent
worse function), and pre-stroke cognitive status [16-item
Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE) [21]; range 1–5, higher scores represent worse
cognitive function]. Medical record data included, sex,
insurance status, risk factors [history of stroke/transient
ischaemic attack, hypertension, coronary artery disease,
atrial fibrillation, high cholesterol, smoking status (never/
former vs current), excessive alcohol consumption], comor-
bidities (myocardial infarction or congestive heart failure,
cancer, chronic obstructive pulmonary disease, dementia or
Alzheimer’s disease, epilepsy, Parkinson’s disease, end-stage
renal disease), BMI, treatment with tissue-type plasminogen
activator (tPA), and nursing home residence before stroke.
The aforementioned risk factors and comorbidities, exclud-
ing diabetes, were summed to create a pre-stroke comorbid-
ity index (range 0–14; higher score represents more
comorbidities). This index has previously been shown to be
associated with post-stroke functional outcome in this
population [15]. Initial stroke severity, measured by the
National Institutes of Health Stroke Scale (NIHSS), was
abstracted from the medical record or retrospectively
calculated using validated methods (range 0–42; higher
scores represent greater severity) [22].
Statistical analysis
Descriptive statistics were calculated for all variables by
diabetes status, and differences were assessed using chi-
squared and Wilcoxon rank-sum tests. Cox proportional
hazards models were used to compare all-cause mortality
and stroke recurrence by diabetes status at 30 days and 1
year after ischaemic stroke. Events were censored at the end
of follow-up, and stroke recurrence was additionally cen-
sored for death. Because functional outcome was constrained
by lower and upper bounds, Tobit regression was used to
examine differences in 90-day ADL/IADL scores by diabetes
status, and logistic regression was used to compare the
dichotomous functional outcome [23]. For all outcomes, we
first ran an unadjusted model including only diabetes.
Models were then sequentially adjusted for sets of prespec-
ified potential confounders identified from the literature
(Supporting Information). In addition, to aid in the interpre-
tation of the results for the models of functional outcome, we
calculated Cohen’s standardized effect size by dividing the
difference in ADL/IADL score by the overall standard
deviation of the ADL/IADL score [24].
All participants provided written informed consent, and
the study was approved by the institutional review boards at
the University of Michigan and the local hospitals.
Results
Figures 1 and 2 show the analytical samples for the outcome
models. Samples sizes were lower for 1-year mortality
because these models were adjusted for cardiovascular risk
factors and thus required complete data for risk factors,
whereas 30-day mortality and 1-year stroke recurrence were
not adjusted for cardiovascular risk factors because of a
limited number of outcome events. There was no difference
between those who did and did not complete a baseline
interview by diabetes status (P=0.12) or initial stroke severity
(P=0.29).
Forty-six percent of people included in the study had a
history of known diabetes, the median (interquartile range)
age was 70 (58–81) years, and 61% were Mexican Amer-
ican. People with diabetes were younger, more likely to be
Mexican American, had a higher average BMI, and a higher
proportion had a history of myocardial infarction/coronary
artery disease, hypertension, high cholesterol, end-stage renal
disease, and congestive heart failure than people without
diabetes (Table 1; P<0.01 for all). People with diabetes were
less likely to have attained an educational status of more than
high school, be a current smoker, use alcohol excessively or
receive tPA treatment, and a lower proportion had a history
of atrial fibrillation and Alzheimer’s/dementia (P<0.01 for
all). Baseline characteristics for the subset used in the
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functional outcome analysis (n=509) were similar to those in
the larger stroke population (Table S1).
All-cause mortality
Risk of 30-day and 1-year mortality was 8.4% and 20.5%
for people with diabetes who experienced stroke and 9.5%
and 20.8% for people without diabetes who experienced
stroke, respectively (Table S2). In unadjusted models,
diabetes was not significantly associated with 30-day (hazard
ratio 0.89, 95% CI 0.61–1.28) or 1-year (hazard ratio 1.04,
95% CI 0.81–1.33) all-cause mortality (Table 2). After
adjustment for demographics, the association between dia-
betes and all-cause mortality became stronger (30-day hazard
ratio 1.44, 95% CI 0.97–2.12; 1-year hazard ratio 1.55,
95% CI 1.19–2.01). This change in association was
attributable primarily to age. The associations between
diabetes and 30-day and 1-year all-cause mortality were
largely unchanged with additional adjustment for socio-
economic status, stroke severity, stroke treatment and risk
factors. Initial NIHSS was associated with an increased risk
of 30-day mortality, while Mexican-American ethnicity was
associated with a lower risk of 30-day mortality. Age, initial
NIHSS, congestive heart failure, and Alzheimer’s/dementia
were associated with a higher risk of 1-year mortality.
Mexican-American ethnicity and tPA treatment were asso-
ciated with a lower risk of 1-year mortality. Effect modifi-
cation by ethnicity was not significant for either mortality
endpoint (P for interaction = 0.61 and 0.31 for 30-day and 1-
year mortality, respectively).
Stroke recurrence
There were 122 recurrent strokes within 1 year of the initial
ischaemic stroke, of which 115 (94%) were recurrent
ischaemic stroke. Risk of 30-day and 1-year stroke recur-
rence was 1.2% and 7.5% for people with diabetes and
1.5% and 5.8% for people without diabetes, respectively
(Table S3). Diabetes was not associated with stroke recur-
rence in crude or adjusted analyses (Table 2). No factors
were significantly associated with 1-year recurrence. Effect
modification by ethnicity was not significant (P=0.37).
Functional outcome
On average, people with and without diabetes had a mean
(SD) ADL/IADL score of 2.48 (0.99) and 2.36 (1.08),
respectively (higher score worse), reflecting mild to moderate
disability (scores reflect ‘some’ to ‘a lot of’ difficulty with
ADLs and IADLs). In the crude model, diabetes was not
significantly associated with functional outcome (b=0.15,
95% CI –0.07 to 0.36; Table 3). After adjustment for
demographics, diabetes became significantly associated with
worse functional outcome, primarily as a result of age
adjustment. Further adjustment for socio-economic status,
stroke severity and tPA treatment resulted in little change in
the association (b=0.25, 95% CI 0.06–0.44). This translated
into a Cohen’s standardized effect size of 0.24 [considered
‘small’ (0.20) to ‘medium’ (0.50)] [24]. Adjustment for
cardiovascular risk factors attenuated the association
between diabetes and functional outcome, causing it to
FIGURE 1 Flow diagram for people who experienced ischaemic stroke who were included in mortality and recurrence analysis. BASIC, Brain Attack
Surveillance in Corpus Christi project.
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become borderline significant. Final adjustment for pre-
stroke factors further attenuated the association, resulting in
a final mean ADL/IADL score difference of 0.11 (95% CI –
0.07 to 0.30). Age, female sex, Mexican-American ethnicity,
initial NIHSS, history of stroke/transient ischaemic attack,
history of Alzheimer’s/dementia, comorbidity index,
IQCODE, and baseline modified Rankin scale were associ-
ated with worse ADL/IADL score at 90 days, whereas tPA
treatment was associated with better ADL/IADL score at 90
days. Effect modification by ethnicity was not significant
(P=0.46). In models considering the dichotomous functional
outcome measure, diabetes was not associated with depen-
dency in unadjusted or adjusted models (Table 4).
Discussion
In this population-based study of people who had experi-
enced ischaemic stroke, the prevalence of diabetes was
46%, which is higher than estimates from other US
population-based studies [25,26]. Risk of 30-day and 1-
year all-cause mortality was 8.4% and 20.5%, respectively,
for people with diabetes who experienced stroke. These
estimates are similar to those found in another diverse, US
population-based stroke study [26]. People who had expe-
rienced stroke with diabetes were roughly 1.5 times more
likely to die at 1 year compared with those without diabetes
after accounting for confounders. A similar pattern was
found for 30-day mortality, although it did not reach
significance. We saw a positive but insignificant association
between diabetes and stroke recurrence that fell within the
range presented by Shou et al. [11] in their meta-analysis.
Mild to moderate disability was noted in people with
diabetes, and there was an association between diabetes and
worse functional outcome that can be interpreted to be a
small to medium difference. This association was explained
by cardiovascular risk factors and pre-stroke physical and
cognitive function, as evidenced by the attenuation of the
association after adjustment for these factors. We did not
find that ethnicity modified the association between diabetes
and stroke outcomes.
FIGURE 2 Flow diagram for people who experienced ischaemic stroke who were included in the functional outcome analysis. BASIC, Brain Attack
Surveillance in Corpus Christi project.
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In the present study, there was no association between
diabetes and mortality in crude analysis; however, partici-
pants with diabetes were significantly younger than those
without diabetes, and younger age was associated with lower
mortality; therefore, after accounting for age and other
demographic factors, diabetes was associated with higher
post-stroke mortality. The inverse association between dia-
betes and age, however, may be unique to populations with
significant minority representation. One US study, with a
sizable proportion of African- American participants, also
found that people with diabetes who experienced ischaemic
stroke were younger than those without diabetes [25]. Other
studies in ischaemic stroke populations found either no age
difference by diabetes status or that participants with
diabetes were significantly older [5,27]. These findings
suggest that the presence and degree of confounding by age
in the association of diabetes and mortality is highly
dependent on the population, and speaks to the critical need
to consider age adjustment when comparing results across
studies.
After adjustment for sociodemographic factors, initial
stroke severity and tPA treatment, diabetes was associated
with worse functional outcome, consistent with prior studies
[10,13,28]; however, after adjustment for the higher burden
Table 1 Baseline characteristics of participants with ischaemic stroke by diabetes status (n=1301)
History of known diabetes
PYes (N=602) No (N=699)
Median (Q1–Q3) age, years 65 (57–77) 73 (61–83) <0.001
Women, n (%) 299 (49.7) 357 (51.1) 0.613
Mexican-American, n (%) 450 (74.8) 339 (48.5) <0.001
Education: more than high school*, n (%) 189 (31.4) 269 (38.7) 0.006
Insured, n (%) 538 (89.4) 638 (91.3) 0.245
Atrial fibrillation, n (%) 70 (11.6) 133 (19.0) <0.001
Myocardial infarction or coronary artery disease*, n (%) 251 (41.7) 201 (28.8) <0.001
Hypertension, n (%) 547 (90.9) 499 (71.4) <0.001
High cholesterol, n (%) 340 (56.5) 254 (36.3) <0.001
History of stroke or TIA, n (%) 166 (27.6) 169 (24.2) 0.162
Cancer, n (%) 62 (10.3) 93 (13.3) 0.095
End-stage renal disease, n (%) 57 (9.5) 18 (2.6) <0.001
Alzheimer’s or dementia*, n (%) 51 (8.5) 95 (13.6) 0.003
Chronic obstructive pulmonary disease, n (%) 66 (11.0) 90 (12.9) 0.290
Congestive heart failure, n (%) 104 (17.3) 75 (10.7) <0.001
Current smoker*, n (%) 105 (17.5) 168 (24.1) 0.004
Excessive alcohol use, n (%) 21 (3.5) 56 (8.0) <0.001
Treated with tPA, n (%) 31 (5.2) 63 (9.0) 0.007
Median (Q1–Q3) initial NIHSS score*, n (%) 4 (2–8) 5 (2–9) 0.244
Median (Q1–Q3) BMI* 30.1 (26.2–35.7) 26.6 (23.6–30.3) <0.001
NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack; tPA, tissue-type plasminogen activator. Data from the
Brain Attack Surveillance in Corpus Christi (BASIC) project (April 2006 to June 2012). *Missing: Education, 0.3%; Myocardial infarction or
coronary artery disease, 0.2%; Alzheimer’s or dementia, 0.2%; Smoking status, 0.3%; Initial NIHSS, 0.1%; BMI, 2.3%.
Table 2 Hazard ratios for the association of diabetes mellitus on all-cause mortality and stroke recurrence after ischaemic stroke
Model
1-year recurrence 30-day mortality 1-year mortality
(n=1295) (n=1295) (n=1260)
Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
Model 1: unadjusted 1.29 (0.81, 2.05) 0.89 (0.61, 1.28) 1.04 (0.81, 1.33)
Model 2: adjusted for demographics 1.30 (0.79, 2.11) 1.41 (0.96, 2.07) 1.55 (1.19, 2.01)
Model 3: Model 2 + socio-economic status 1.28 (0.79, 2.09) 1.41 (0.96, 2.07) 1.55 (1.19, 2.01)
Model 4: Model 3 + stroke severity 1.27 (0.78, 2.07) 1.44 (0.97, 2.12) 1.63 (1.25, 2.13)
Model 5: Model 4 + tPA – – 1.61 (1.23, 2.09)
Model 6: Model 5 + cardiovascular risk factors – – 1.47 (1.09, 1.97)
tPA, tissue-type plasminogen activator.
Data from the Brain Attack Surveillance in Corpus Christi (BASIC) project (April 2006 to June 2012). Due to limited events, 1-year
recurrence and 30-day mortality were only adjusted through stroke severity, and 30-day recurrence was not considered. Demographics
include: age, sex, race-ethnicity. Socio-economic status includes: education, insurance status. Cardiovascular risk factors include: history of
stroke/ transient ischaemic attack, myocardial infarction/coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease,
congestive heart failure, end-stage renal disease, cancer, Alzheimer’s/dementia, high cholesterol, hypertension, alcohol excess, smoking
status, BMI.
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of cardiovascular risk factors and worse pre-stroke physical
and cognitive function in those with diabetes, the diabetes–
functional outcome association was attenuated and no longer
significant; therefore, improving adherence to existing guide-
lines for treating cardiovascular risk factors and preventing
comorbidities in people with diabetes may improve post-
stroke functional outcomes [29]. Unlike many studies, which
have used the modified Rankin scale to assess function, in the
present study we used a measurement of ADLs/IADLs. The
modified Rankin scale is typically categorized so that poor
outcome includes disability or death. Because diabetes is
associated with post-stroke mortality, it is not possible to
disentangle the impact of diabetes on function vs mortality
when a combined endpoint, such as the modified Rankin
scale, is used. Measuring functional outcome using a scale
that focuses on the ability to perform ADLs and IADLs
among survivors allowed us to identify an association
between diabetes and functional disability separate from
the association with mortality.
Although not part of our original hypothesis, we found
that people with diabetes were significantly less likely to
receive tPA treatment than people without diabetes, consis-
tent with findings from other studies [30,31]. A possible
explanation for this is that differences in eligibility for tPA
treatment existed for those with and without diabetes.
Alternatively, there may be physician concern about an
increased risk of haemorrhage in people with diabetes after
tPA treatment [31]; however, it has been shown that tPA
improves outcomes in people with diabetes [30]. Therefore,
improving thrombolytic treatment in eligible people with
diabetes who experience stroke should be a priority. Addi-
tionally, because Mexican-American people who experience
stroke have both a higher prevalence of diabetes and worse
functional outcomes compared with non-Hispanic white
people, increasing the frequency of tPA treatment in eligible
people with diabetes could improve functional outcomes in
Mexican-American people and lessen the disparity in stroke
outcomes [15].
The strengths of the present study include its population-
based design, ethnic diversity and thorough adjustment for
confounding factors. Limitations include the fact that,
because of the low number of events, we were not able to
adjust for all confounders in models for 30-day mortality and
1-year recurrence. In addition, we did not have information
on diabetes treatment and medication adherence or severity
and duration of diabetes. Ascertainment of known diabetes
was based solely on history in the medical record and
therefore it is possible that some people had undiagnosed
diabetes. We have previously documented, however, that
access to care in this community is high, which suggests that
this is not a major concern [20]. We also did not have
information on HbA1c or glucose levels, and were not able to
differentiate between Type 1 and Type 2 diabetes, although
the majority of participants would be expected to have Type
2 diabetes. Given the observational nature of this study, we
Table 3 Results of multivariable models of the association of diabetes





Model 1: unadjusted 0.15 (-0.07 to 0.36)
Model 2: adjusted for demographics 0.22 (0.01 to 0.43)
Model 3: Model 2 + socioeconomic
status
0.21 (0.00 to 0.41)
Model 4: Model 3 + stroke severity 0.27 (0.08 to 0.45)
Model 5: Model 4 + tPA 0.25 (0.06 to 0.44)
Model 6: Model 5 + cardiovascular
risk factors
0.17 (-0.02 to 0.36)
Model 7: Model 6 + pre-stroke factors* 0.11 (-0.07 to 0.30)
IA, transient ischaemic attack; tPA, tissue-type plasminogen
activator.
Data from the Brain Attack Surveillance in Corpus Christi
(BASIC) project (April 2006 to June 2012). Estimates given
were derived as the regression coefficients from the model for
average activities of daily living (ADL)/instrumental activities of
daily living (IADL) score. Estimates represent the difference in
mean ADL/IADL comparing people with diabetes to people
without diabetes. Demographics include: age, sex, race-ethni-
city, marital status. Socio-economic status includes: education,
insurance status. Cardiovascular risk factors include: history of
stroke/ transient ischaemic attack, myocardial infarction/coro-
nary artery disease, atrial fibrillation, high cholesterol, hyper-
tension, smoking status, BMI. Pre-stroke factors include:
pre-stroke nursing home residence, modified Rankin scale,
Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE), comorbidity index.
*Pseudo-R2 = 0.19.
Table 4 Results of Multivariable Models of the Association of




Model 1: Unadjusted 1.065 (0.739 to 1.535)
Model 2: Adjusted for
demographics
1.184 (0.778 to 1.802)
Model 3: Model 2 +
socioeconomic status
1.167 (0.766 to 1.779)
Model 4: Model 3 + stroke severity 1.309 (0.836 to 2.051)
Model 5: Model 4 + tPA 1.286 (0.82 to 2.016)
Model 6: Model 5 +
cardiovascular risk factors
1.175 (0.712 to 1.938)
Model 7: Model 6 +
pre-stroke factors
1.040 (0.611 to 1.77)
The Brain Attack Surveillance in Corpus Christi (BASIC)
Project (April 2006-June 2012). Estimates given were
derived as the regression coefficients from the model for
average activities of daily living/instrumental activities of
daily living score. ORs represent the odds of dependence
(defined as an ADL/IADL score ≥3) comparing patients with
and without diabetes. Demographics include: age, sex, race-
ethnicity, marital status. Socioeconomic status includes:
education, insurance status. Cardiovascular risk factors
include: history of stroke/TIA, myocardial infarction/coronary
artery disease, atrial fibrillation, high cholesterol, hyperten-
sion, smoking status, BMI. Pre-stroke factors include: pre-
stroke nursing home residence, mRs, IQCODE, comorbidity
index.
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cannot exclude the possibility of residual confounding. It is
also possible that we over-adjusted in that some variables in
our multivariable models may be on the causal pathway
between diabetes and stroke outcomes. Furthermore, we did
not have data on ischaemic stroke subtype, which is
associated with diabetes and could therefore confound the
observed associations.
The present study provides a comprehensive overview of
the association between diabetes and stroke outcomes in a bi-
ethnic population. We found positive associations between
diabetes and all-cause mortality and between diabetes and
worse functional outcome, and no significant association
between diabetes and stroke recurrence. Although associa-
tions between diabetes and stroke outcomes were similar by
ethnicity, the high prevalence of diabetes in Mexican-
American people who experienced stroke suggests that
diabetes is an important target for addressing stroke outcome
disparities in this population.
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